title: 4-Bromo-2,5-dimethoxyphenethylamine (2C-B): presence in the recreational drug market in Spain, pattern of use and subjective effects.
abstract: 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) is a psychoactive analogue of mescaline that is becoming increasingly popular as a rave and club drug. We investigated its presence in the illicit drug market in Spain, its pattern of use and profile of subjective effects. Drug material was analysed for 2C-B and information on pattern of use and subjective effects was obtained from recreational users. Scores were statistically compared with previously collected data on psychostimulants (d-amphetamine), entactogens (MDMA) and psychedelics (ayahuasca and Salvia divinorum). The percentage of samples containing 2C-B doubled between 2006 and 2009, evolved from powder to tablet form and showed low falsification rates. Respondents reported taking 2C-B orally in doses of about 20 mg. Subjective effects involved perceptual modifications analogous to those observed after ayahuasca and salvia but absent after amphetamine and MDMA. Pleasure and sociability effects did not differ from those after MDMA and incapacitation was lower than for the psychedelics used as comparators. In conclusion, we found 2C-B is consistently present in the illicit drug market in Spain. While it elicits perceptual modifications that are analogous to other psychedelics, the lower impairment and higher pleasurable effects make it comparable with entactogens.
authors.affiliation: Centro de Salud Puerta Bonita I, Madrid, Spain. caudevilla@gmail.com
authors.forename: Fernando
authors.initials: F
authors.lastname: Caudevilla-Gálligo
authors.forename: Jordi
authors.initials: J
authors.lastname: Riba
authors.forename: Mireia
authors.initials: M
authors.lastname: Ventura
authors.forename: Débora
authors.initials: D
authors.lastname: González
authors.forename: Magí
authors.initials: M
authors.lastname: Farré
authors.forename: Manel J
authors.initials: MJ
authors.lastname: Barbanoj
authors.forename: José Carlos
authors.initials: JC
authors.lastname: Bouso
mesh_terms: D000328:Adult; D003617:Dangerous Behavior; D015198:Designer Drugs / Q000008:administration & dosage* / Q000032:analysis / Q000191:economics / Q000494:pharmacology*; D004118:Dimethoxyphenylethylamine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000032:analysis / Q000191:economics / Q000494:pharmacology; D058999:Drug-Seeking Behavior; D005260:Female; D006213:Hallucinogens / Q000008:administration & dosage / Q000032:analysis / Q000191:economics / Q000494:pharmacology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010469:Perceptual Distortion / Q000187:drug effects; D015995:Prevalence; D011619:Psychotropic Drugs / Q000008:administration & dosage* / Q000032:analysis / Q000191:economics / Q000494:pharmacology*; D012189:Retrospective Studies; D057566:Self Report; D013030:Spain / Q000453:epidemiology; D019966:Substance-Related Disorders / Q000453:epidemiology; D013607:Tablets; D055815:Young Adult
chemical_list: D015198:Designer Drugs; D004118:Dimethoxyphenylethylamine; D006213:Hallucinogens; D011619:Psychotropic Drugs; D013607:Tablets; C079321:2-(4-bromo-2,5-dimethoxyphenyl)ethylamine